Biotechs over $5 that are up 220% or
more
13 declined
5 rose.
The
research I've done on the way the strongest stocks topped
out
in 1999-2000 shows several things:
1) Weekly OBV non-confirmations of new highs
gave the
most
timely Sells on these stocks. I will be posting weekly
data
on all the strongest biotechs on our data page. It
will
be included in the regularly weekly data.
2)
Many of the 1999-2000 stocks were up 8x-10x their 12-month
lows.
3)
25% were more than 48% above their 21-day ma.
4)
Closing Power trend-breaks in the very strongest stocks
was
the most common way one could have know that a
top
had been made.
5) In the daily charts, Closing Power NCs and OBV
NCs occurred
at
1/2 the tops.
6)
Head and shoulders in the daily charts appreared In 1/4 of
the
1999-2000 super stocks as they were topping out.
7)
False breakouts occurred in 1/4 of the these stocks.
8)
The declines that resulted were swift and punishing to the
longs
who ignored them. 30%-50% declines within three months
were
the norm. Some were even more severe.
Biotechs over $5 that are up 220%
or more
1/13/2014
1/17/2014 One Day
1/22/2013-1/17/2014
Pct
Gain Pct Gain
--------------------------------------------------------------
ICPT
445.83
292.88
+5% +756%
pulled back to top of gap.
------->BCRX
10.51
10.80
-----
+562%
channel breakout
13.53
is 5-year high - OBV confirming.
BioCryst Pharmaceuticals 40 employees Durham, NC
http://www.biocryst.com
-
develops novel drugs that block key enzymes involved in the pathogenesis of
diseases.
-
in Phase III clinical trials for acute influenza;
------>ARWR
12.32
12.31
-3%
+472%
on channel breakout run
All-time
high. OBV is confirming.
Arrowhead
Research Corp. 54 employees http://www.arrowheadresearch.com
ARC-520,
an RNAi-based therapeutic that has completed a Phase 1 clinical trial for the
treatment
of chronic hepatitis B virus (HBV) infection; and
Adipotide,
which is in Phase I clinical trial for the treatment for obesity.
IDRA
5.03
4.34
-3%
+478%
at rising 21-dma
------>PBYI
112.26
125.81
+3%
+414%
B10/B12/B20/B24 run
All-time
high. OBV is confirming.
http://www.pumabiotechnology.com
49 employees LA,CA
Engages
in the acquisition, development, and licensing of products for the treatment of various
forms
of cancer. Its drug candidates include PB272 (neratinib (oral)) for the treatment of
advanced
breast cancer patients and non-small cell lung cancer patients; and PB272
(neratinib
(intravenous)) for the treatment of advanced cancer patients
ACAD
23.32
24,04
-1%
+323%
stalled at 65-dma
30
is 5-year high. OBV is weakening.
SNMX 5.69
7.30 +3%
+322%
channel breakout run
8 is 5-year high
.
NPSP
35.0
35.67
-1%
+290%
double top? IP21= .45
triangle
pattern old highs. Ususally bullish
OBV is lagging.
GALE
7.24
7.00
-7%
+286%
Heavy red distribution. CP weak.
OBV H/S pattern.
ALNY
87.36
-1%
+273%
gap held and reversal.
5-year
high. Wkly OBV is confirming. .
ANAC
17.52
19.38 +2%
+270%
Wkly OBV confirming. Both UP condition.
CLVS
76.26
72.90
-3%
+252%
at 7-month resistance
Resistance is 80-86 OBV is lagging.
CLDX
25.66
28.32
-1% +279% trying to
resume uptrend,. 39 = 12m high
Weekly OBV is lagging
ISIS
47.22
47.14
-2%
+241%
at top of price channel IP21 = .63
OBV
is lagging.
CYTR
7.47
7.04
+1%
+228%
Heavy red distribution. CP weak.
--------------------------------------------------------------------------------------------------------------
New
Bios up over 220%
--------------------------------------------------------------------------------------------------------------
-------> ANIK
37.39
-5%
+248%
at resistance-39. Watch.
Weekly OBV is confirming. CP is
lagging.
106
employees - Bedford, MA http://www.anikatherapeutics.com
Products
for tissue protection, healing, and repair. Its products are based
on
hyaluronic acid (HA), a naturally occurring biocompatible polymer found in the body.
VNDA
13.27
-----
+222%
at resistance-13-14.
17 is 5-year high... OBV is lagging.
INCY
61.87
-3% +230%
channel breakout run IP21=.299
Weekly
OBV has been slow to confirm
Also interesting high IP21 Biotechs
IP21
.592 NBIX 19.64
+.05 78 employees SD< CA Elagolix, a Phase III drug for
endometriosis
.403
PSTI
4.34 -.04 142 employees Israel
company?s PLX cells function as a drug delivery platform
.473
GEVA 96.48 +3.86 B10/B12 run. 115 employees
Lexington, MASS
Sebelipase
alfa, a recombinant form of human lysosomal acid lipase (LAL) is under
Phase
III clinical trials for the treatment of early and late onset LAL Deficiency..
.429
NPSP
35.67 -.20 readying an explosion past 37 AI/200=154
149 employ...NJ
Natpara
that is under Phase 3 clinical trial for the treatment of adult hypoparathyroidism
.453 SGMO
19.64 -.20 AI/200=145 looks very good. Multiple Buys
Richmond, CA 84 employees
ZFP
TFs) proteins that could be used to turn genes on or off.
.429
VRTX
82.09 +1.09 resistance up to 90.
.417 ALXN 139.71 -.10 new high AI/200=159
-------------------------------------------------------------------------------------------------------------------------------
GILD
78.4 +.50 Biggest FBIOX
holding.
|
|
|
|
|